インターロイキン8A受容体

WordNet

a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
any of several lymphokines that promote macrophages and killer T cells and B cells and other components of the immune system

PrepTutorEJDIC

=sense organ / 受信装置

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 進行黒色腫に対するインターロイキン2および実験的免疫学的アプローチinterleukin 2 and experimental immunotherapy approaches for advanced melanoma [show details]
…chemotherapy (biochemotherapy) , and various toxicity reduction agents, such as (TNFR) and interleukin-1 receptor (IL-1R) antagonists. Although activity was seen with all of these approaches, none of these …
2. β-2アドレナリン受容体機能不全および喘息の多型性beta 2 adrenergic receptor dysfunction and polymorphism in asthma [show details]
… cytokines, such as interleukin 1-beta ; Beta-2 receptor number is increased by in vitro exposure to glucocorticoids ; The possibility that medication-induced changes in beta receptor density or signal …
3. 腫瘍壊死因子受容体-1関連周期性発熱症候群（TRAPS）tumor necrosis factor receptor 1 associated periodic syndrome traps [show details]
… There are a few case reports of successful treatment of patients with TRAPS using the interleukin (IL) 6 receptor antagonist tocilizumab . Given the limited data, we would reserve this option for unusual …
4. 心不全におけるアンギオテンシン変換酵素阻害剤およびアンギオテンシン受容体拮抗剤：作用機序angiotensin converting enzyme inhibitors and receptor blockers in heart failure mechanisms of action [show details]
…angiotensin II receptor (AT1) is compatible with enhanced local activity of angiotensin II . The reduction in AT1 receptor density paralleled the reduction in the density of b1 receptors.… increased levels of various proinflammatory cytokines, including tumor necrosis factor alpha and interleukin-1 and -6. Although ACE inhibitors have a beneficial effect in HF, it is uncertain if they alter …
5. 免疫不全症を引き起こすCD3／T細胞受容体複合体疾患cd3 t cell receptor complex disorders causing immunodeficiency [show details]
… which are ligands for killer cell lectin-like receptors and killer cell immunoglobulin-like receptors on natural killer (NK) cells,… and interleukin 2-inducible T-cell kinase (ITK) may cause major T cell dysfunction .…

English Journal

Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.

Liu C1,2, Kanamaru Y1, Watanabe T1, Tada N3, Horikoshi S1, Suzuki Y1, Liu Z2, Tomino Y1.
Clinical and experimental immunology.Clin Exp Immunol.2015 Sep;181(3):407-16. doi: 10.1111/cei.12647. Epub 2015 Jul 2.
The Fc receptor I for IgA (FcαRI) down-regulates humoral immune responses and modulates the risk of autoimmunity. This study aimed to investigate whether FcαRI targeting can affect progression of pristine-induced lupus nephritis. In the first experiment (early intervention), four groups of animals
PMID 25907714

Novel Human Cytomegalovirus Viral Chemokines, vCXCL-1s, Display Functional Selectivity for Neutrophil Signaling and Function.

Heo J1, Dogra P1, Masi TJ1, Pitt EA1, de Kruijf P2, Smit MJ2, Sparer TE3.
Journal of immunology (Baltimore, Md. : 1950).J Immunol.2015 Jul 1;195(1):227-36. doi: 10.4049/jimmunol.1400291. Epub 2015 May 18.
Human CMV (HCMV) uses members of the hematopoietic system including neutrophils for dissemination throughout the body. HCMV encodes a viral chemokine, vCXCL-1, that is postulated to attract neutrophils for dissemination within the host. The gene encoding vCXCL-1, UL146, is one of the most variable g
PMID 25987741

A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.

Opfermann P1, Derhaschnig U, Felli A, Wenisch J, Santer D, Zuckermann A, Dworschak M, Jilma B, Steinlechner B.
Clinical and experimental immunology.Clin Exp Immunol.2015 Apr;180(1):131-42. doi: 10.1111/cei.12488.
Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischaemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce. The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy of reparixin to suppress IRI and
PMID 25402332